<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870100</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1222-101</org_study_id>
    <nct_id>NCT03870100</nct_id>
  </id_info>
  <brief_title>The PK/PD Study of A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects</brief_title>
  <official_title>Use the Protocol Title. The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study Following A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Single Center, Randomized, Double-Blind, Dose Escalation, Placebo Parallel
      Controlled PhaseⅠClinical study to Evaluate the Safety, Tolerability and Pharmacokinetics,
      Pharmacodynamics with A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects.

      The primary objective of this study is to investigate the safety and tolerability of a range
      of subcutaneous SHR-1222 in healthy subjects. Secondary objectives are to determine the
      pharmacokinetics (PK) and pharmacodynamics(PD) profile of SHR-1222 in healthy subjects
      including assessment of immunogenicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      50 adult healthy subjects with 5 dose groups will be enrolled in the study, including six
      subjects in the lowest dose group, four of whom received the SHR-1209 and two of whom
      received the placebo. The other three groups have 11 subjects in each group, 9 administered
      SHR-1222 and 2 administered placebo. The primary endpoint is the Safety and Tolerability :
      adverse events, vital signs, physical examination, laboratory examination, 12 lead
      electrocardiogram, injection site reactions, etc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Actual">January 6, 2020</completion_date>
  <primary_completion_date type="Actual">October 14, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number &amp; proportion of subjects with adverse events [Time Frame: dose administration to 85 days after dose administration] Safety and Tolerance: Number &amp; proportion of subjects with adverse events</measure>
    <time_frame>Dose administration to 85 days after dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-time to maximum concentration (Tmax)</measure>
    <time_frame>Pre-dose to 85 days after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-maximum concentration (Cmax)</measure>
    <time_frame>Pre-dose to 85 days after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-area under curve (AUC)</measure>
    <time_frame>Pre-dose to 85 days after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter-change in serum C-telopeptide (sCTx) from baseline</measure>
    <time_frame>Pre-dose to 85 days after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter-change in aminoterminal propeptide type-1 procollagen (P1NP) from baseline</measure>
    <time_frame>Pre-dose to 85 days after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter-change in osteocalcin from baseline</measure>
    <time_frame>Pre-dose to 85 days after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter-change in bone-specific alkaline phosphatase (BSAP) from baseline</measure>
    <time_frame>Pre-dose to 85 days after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter-change in areal bone mineral density of lumbar spine (L1-L4 mean T value) from baseline</measure>
    <time_frame>Pre-dose to 85 days after dose administration</time_frame>
    <description>by dualenergy X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter-change in areal bone mineral density of collum femoris (T value) from baseline</measure>
    <time_frame>Pre-dose to 85 days after dose administration</time_frame>
    <description>by dualenergy X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter-change in volumetric bone mineral density of lumbar spine (L1-L4 mean T value) from baseline</measure>
    <time_frame>Pre-dose to 85 days after dose administration</time_frame>
    <description>by quantitative computed tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter-change in volumetric bone mineral density of collum femoris (T value) from baseline</measure>
    <time_frame>Pre-dose to 85 days after dose administration</time_frame>
    <description>by quantitative computed tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibody concentration</measure>
    <time_frame>Pre-dose to 85 days after dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1222 dose 1 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1222 dose 2 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1222 dose 3 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1222 dose 4 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1222 dose 5 versus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1222</intervention_name>
    <description>Pharmaceutical form: water injection Route of administration: subcutaneous</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: water injection Route of administration: subcutaneous</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent;

          -  Male or postmenopausal female;

          -  Age ≥45 and ≤59 years old;

          -  The body mass index (BMI) ≥18.5kg/m2 and ≤28 kg/m2;

          -  T value of areal bone mineral density on any lumbar spine (L1-L4) or collum
             femoris&gt;-2.5 and &lt;-1;

          -  The comprehensive physical examination is eligible or slightly abnormal but the
             researchers determine no clinical implication;

          -  No smoking, alcohol or drugs abuse.

        Exclusion Criteria:

          -  Any disease affecting bone metabolism;

          -  Past medical history of cerebral infarction or cerebral arterial thrombosis;

          -  Past medical history of myocardial infarction;

          -  Administration of the following drugs within 6m: Hormone replacement therapy,
             Calcitonin Parathyroid hormone (or any derivative), Supplemental Vitamin D&gt;1,000
             IU/day, Glucocorticosteroids (inhaled or topical corticosteroids administered more
             than 2 weeks before the enrollment date are allowed), Anabolic steroids, Calcitriol
             and available analogues, thiazide diuretics;

          -  Administration of the following drugs within 12m: Bisphosphonates, Fluoride for
             osteoporosis;

          -  A bone fracture within the previous 6 months;

          -  A lumbar spine L1-L4 or femoral neck T-score ≤-2.5;

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma pancreatic
             acyl transferase (GGT) or total bilirubin, more than 1.5 x ULN during screening;

          -  3 months prior to screening involved in any drug clinical subjects;

          -  Subjects determined by the researchers have any food, dietary supplement or drugs that
             affect SHR-1222 absorption, distribution, metabolism and excretion in 4 weeks prior to
             screening or within 5 half-lives;

          -  Serious infection, trauma or major surgery in 4 weeks prior to screening;

          -  A surgery plan during the study;

          -  Blood donation and transfusion in 3 months prior to screening;

          -  Unstable thyroid dysfunction in 6 months prior to screening;

          -  Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination,
             hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were
             positive;

          -  Intolerant to venous blood collection;

          -  A clinical history of drug allergy or a history of atopic allergic diseases (asthma,
             urticaria, eczema dermatitis) or a known allergy to experimental or similar

          -  Subjects with any other situation should not be involved, which determined by the
             researchers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiguang Zhou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>2nd Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>June 14, 2020</last_update_submitted>
  <last_update_submitted_qc>June 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

